Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.00% $26.68
America/New_York / 31 des 1970 @ 19:00
RATING 2022-03-18 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/20 | 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -6.56 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.12x |
Company: PE -6.56 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 26.08 - 27.28 ( +/- 2.26%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-03-07 | Breitmeyer James B | Sell | 1 250 | Common Stock |
2022-03-07 | Breitmeyer James B | Sell | 9 375 | Stock Option (Right to Buy) |
2022-03-07 | Breitmeyer James B | Sell | 6 250 | Stock Option (Right to Buy) |
2022-03-07 | Breitmeyer James B | Sell | 9 000 | Stock Option (Right to Buy) |
2022-03-07 | Breitmeyer James B | Sell | 10 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
0.00 |
Last 100 transactions |
Buy: 446 833 | Sell: 2 096 567 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $26.68 (0.00% ) |
Volume | 11.25 mill |
Avg. Vol. | 3.10 mill |
% of Avg. Vol | 363.20 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.